• 1. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

3-Butenoic acid, phenylmethyl ester (CAS No. 86170-45-8): A Comprehensive Review in Modern Chemical Biology and Medicine

The compound 3-Butenoic acid, phenylmethyl ester, identified by the chemical abstracts service number CAS No. 86170-45-8, represents a fascinating molecule with significant implications in the realms of chemical biology and pharmaceutical research. This compound, also known as phenylacrylic acid methyl ester, belongs to the class of β-keto esters and has garnered attention due to its unique structural and functional properties. The synthesis, biological activities, and potential therapeutic applications of this molecule have been extensively studied, making it a subject of considerable interest in contemporary scientific discourse.

In recent years, the exploration of 3-Butenoic acid, phenylmethyl ester has been closely tied to advancements in drug discovery and molecular pharmacology. Its molecular framework, characterized by a conjugated system of a butenoic acid moiety linked to a phenylmethyl (benzyl) group, offers versatile interactions with biological targets. This structural configuration has been exploited in the design of novel compounds targeting various pathological conditions. For instance, studies have highlighted its potential role in modulating enzyme activities and receptor interactions, which are pivotal in the development of therapeutic agents.

The chemical synthesis of 3-Butenoic acid, phenylmethyl ester involves well-established organic reactions, including esterification and condensation processes. Researchers have optimized these synthetic pathways to achieve high yields and purity, ensuring that the compound is suitable for further biological evaluation. The use of advanced spectroscopic techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) has been instrumental in confirming the structural integrity of the synthesized compound. These methodologies provide detailed insights into the molecular dynamics and conformational preferences of 3-Butenoic acid, phenylmethyl ester, facilitating a deeper understanding of its reactivity and interaction with biological systems.

Biological investigations into 3-Butenoic acid, phenylmethyl ester have revealed intriguing properties that position it as a promising candidate for pharmaceutical development. One notable area of research has focused on its potential as an inhibitor of specific enzymes implicated in inflammatory and degenerative diseases. For example, preliminary studies suggest that this compound may interfere with the activity of cyclooxygenase (COX) enzymes, which are key players in the prostaglandin biosynthesis pathway. By modulating COX activity, 3-Butenoic acid, phenylmethyl ester could potentially mitigate inflammatory responses without the side effects associated with traditional nonsteroidal anti-inflammatory drugs (NSAIDs).

Additionally, the benzyl group in 3-Butenoic acid, phenylmethyl ester provides a handle for further chemical modifications, enabling the synthesis of derivatives with enhanced biological activity. Researchers have explored strategies to attach various functional groups to this aromatic ring, thereby tailoring the compound’s pharmacokinetic properties. Such modifications have led to the development of novel molecules with improved solubility, bioavailability, and target specificity. These advancements underscore the versatility of 3-Butenoic acid, phenylmethyl ester as a scaffold for drug design.

The pharmacological profile of 3-Butenoic acid, phenylmethyl ester has also been examined in vitro using cell-based assays. These studies have demonstrated its ability to interact with specific cellular receptors and ion channels, suggesting potential applications in neurological disorders. For instance, its binding affinity for certain G-protein coupled receptors (GPCRs) has been reported in preliminary screenings conducted by academic institutions and pharmaceutical companies. Such interactions may pave the way for new therapeutic strategies targeting conditions like depression and anxiety disorders.

In vivo studies have further validated the therapeutic potential of 3-Butenoic acid, phenylmethyl ester. Animal models have been employed to assess its efficacy in reducing inflammation and pain without significant toxicity. These findings are particularly encouraging given the growing demand for safer alternatives to conventional therapeutics. The compound’s ability to cross the blood-brain barrier has also been explored in some contexts, raising possibilities for its use in central nervous system (CNS) disorders.

The future direction of research on 3-Butenoic acid, phenylmethyl ester is likely to be shaped by interdisciplinary collaborations between chemists and biologists. Advances in computational chemistry and artificial intelligence are expected to accelerate the discovery process by predicting molecular interactions and optimizing drug-like properties more efficiently than traditional methods alone could achieve. Furthermore，the integration of high-throughput screening technologies will enable researchers to rapidly assess large libraries of compounds for their biological activity.

In conclusion,3-Butenoic acid, phenylmethyl ester (CAS No 86170 45 8) represents a compelling molecule with broad applications in chemical biology and medicine。 Its unique structural features， coupled with promising biological activities， make it an attractive candidate for further exploration。 As research continues， we can anticipate more refined insights into its mechanisms of action， leading to innovative therapeutic interventions that address unmet medical needs。

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)